Comparison · NCT00130247-sae
4-Month Arm vs 6-Month Arm: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 4-Month Arm vs 6-Month Arm: serious adverse events. Trial comparisons, record NCT00130247-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00130247-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0969 | 0.0629 | 0.146 | wilson | |
| Risk in group 2 | 0.111 | 0.0745 | 0.162 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0142 | -0.0758 | 0.0474 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.872 | 0.488 | 1.56 | log | |
| Odds ratio, group 1 over group 2 | 0.859 | 0.449 | 1.64 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on 4-Month Arm than on 6-Month Arm | 70.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 4-Month Arm | Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks. | 19 | 196 | EG000 |
| Group 2 | 6-Month Arm | Daily treatment with INH, rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks. | 22 | 198 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 6 years
Source ClinicalTrials.gov
Trial
- Title
- Tuberculosis Treatment Shortening Trial
- NCT number
- NCT00130247
- Phases
- PHASE3
- Conditions
- Tuberculosis
- Interventions
- Ethambutol, Isoniazid, Pyrazinamide, Rifampin
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2010-01-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00130247?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00130247-sae